SOLUS INC proposes an HE/HTI- and EMF-activatable, BW/CW warhead airborne intercept submunitions design based on TRIPOL agent defeat technology. A range of potential warhead-deliverable biological and chemical warfare agents (BWA) are resistant to defeat, even by high energy ionizing radiation and microwave exposure. 'Late descent phase' intercepts of intercontinental, and especially theater ballistic warheads may potentially involve survival, airborne dispersal, and settling of debris-embedded agents of mass destruction over populated terrain. Therefore, technologies which enhance vulnerability of CW/BW warheads and which insure lethality of BW/CW agents within the airborne intercept debris field are essential in the era of bioengineered weaponry. A revolutionary polymer design is proposed as a carrier of reactive chemical moieties that are generated within an ionized fusion plasma during intercept-triggered high thermal incendiary blast propagation The technology provides for broad agent spectrum multimechanistic kill via both chemoenergetic and ionization pathways. In addition, due to the incorporation of RF-transducing 'trigger' polymers in the TRIPOL design, the agent defeat kill components generated during an intercept HTI detonation can be hyperactivated by inclusion of a compact, high-power, RF-generating explosively-pumped flux compression generator within the intercept agent defeat submunitions design. Anticipated Benefits/Commercial Applications: The proposed HTI and EMF-activatable molecular kill-enhancement BWA defeat technology is expected to present a broad range of defense applications in the areas of counterforce and counterstrike ordinance, in counterproliferation defeat of BWA production and storage facilities, and in both long range and theater defense applications. Post Sept. 11 market studies indicate a combined defense-military-government and commercial agent defeat market of $800 million in North America alone. DOD acquisitions markets for the TRIPOL Technology include theater intercept and counterforce neutralization of biothreat weaponry and agent storage and production facilities, counterproliferation interdiction activities, as well as BWA neutralization in depots, R&D storage sites, contaminated bases and post-strike/post-conflict theater terrain. In Phase III, our company will form partnerships with major defense contractors in order to pursue incorporation of the TRIPOL technology into evolving theater intercept submunitions designs. The commercial market opportunities for the TRIPOL technology extend well beyond military, DOD, and intelligence community customers, to homeland defense, industrial HAZMAT and Weapons of Mass Destruction (WMD) First Responder Forces. The potential market scope for TRIPOL is thus deemed extensive, particularly since this technology has no equivalent commercial sector competitors in terms of effectiveness and breath of applications scope for neutralization of both BW and CW threats.
Keywords: TRIPOL Agent Defeat Technology, HTI/EMF activated agent defeat, chemothermal reactive species,, exothermic destruction, ionization fusion plasmas, compression flux generators
